These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10953057)

  • 1. Communication between multiple drug binding sites on P-glycoprotein.
    Martin C; Berridge G; Higgins CF; Mistry P; Charlton P; Callaghan R
    Mol Pharmacol; 2000 Sep; 58(3):624-32. PubMed ID: 10953057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein.
    Martin C; Berridge G; Mistry P; Higgins C; Charlton P; Callaghan R
    Br J Pharmacol; 1999 Sep; 128(2):403-11. PubMed ID: 10510451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.
    Pascaud C; Garrigos M; Orlowski S
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):351-8. PubMed ID: 9657975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities.
    Shapiro AB; Ling V
    Eur J Biochem; 1997 Nov; 250(1):130-7. PubMed ID: 9432000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein.
    Martin C; Higgins CF; Callaghan R
    Biochemistry; 2001 Dec; 40(51):15733-42. PubMed ID: 11747450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
    Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence.
    Wang EJ; Casciano CN; Clement RP; Johnson WW
    Biochim Biophys Acta; 2000 Aug; 1481(1):63-74. PubMed ID: 10962093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.
    Shapiro AB; Fox K; Lam P; Ling V
    Eur J Biochem; 1999 Feb; 259(3):841-50. PubMed ID: 10092872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation.
    Sharom FJ; Lu P; Liu R; Yu X
    Biochem J; 1998 Aug; 333 ( Pt 3)(Pt 3):621-30. PubMed ID: 9677321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation.
    Piwnica-Worms D; Rao VV; Kronauge JF; Croop JM
    Biochemistry; 1995 Sep; 34(38):12210-20. PubMed ID: 7547962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.
    Garrigos M; Mir LM; Orlowski S
    Eur J Biochem; 1997 Mar; 244(2):664-73. PubMed ID: 9119038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine.
    Ferry DR; Malkhandi PJ; Russell MA; Kerr DJ
    Biochem Pharmacol; 1995 Jun; 49(12):1851-61. PubMed ID: 7598747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein.
    Shapiro AB; Ling V
    Eur J Biochem; 1998 May; 254(1):189-93. PubMed ID: 9652413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein.
    Shapiro AB; Ling V
    Eur J Biochem; 1998 May; 254(1):181-8. PubMed ID: 9652412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells.
    Malkhandi J; Ferry DR; Boer R; Gekeler V; Ise W; Kerr DJ
    Eur J Pharmacol; 1994 Dec; 288(1):105-14. PubMed ID: 7705462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport.
    Sharom FJ; Yu X; DiDiodato G; Chu JW
    Biochem J; 1996 Dec; 320 ( Pt 2)(Pt 2):421-8. PubMed ID: 8973548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet.
    Qu Q; Sharom FJ
    Biochemistry; 2002 Apr; 41(14):4744-52. PubMed ID: 11926837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter.
    Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
    Pharm Res; 1998 Jul; 15(7):1001-6. PubMed ID: 9688051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter.
    Romsicki Y; Sharom FJ
    Biochemistry; 2001 Jun; 40(23):6937-47. PubMed ID: 11389609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
    Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
    Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.